Previous close | 35.18 |
Open | 35.21 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 35.05 - 36.80 |
52-week range | 23.45 - 37.91 |
Volume | |
Avg. volume | 22,419 |
Market cap | 69.816B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 54.34 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.39 (1.06%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer